The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2020 | Significance of MRD in CLL
Tanya Siddiqi, MD, of the City of Hope National Medical Center, Duarte, CA, explores the use of minimal residual disease (MRD) testing in the clinic for chronic lymphocytic leukemia (CLL) patients, and its use in determining the endpoint for treatment. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
